• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, June 5, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Study: palliative care provided at point of oncology surgery does not improve patient outcomes

Bioengineer by Bioengineer
May 10, 2023
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

One of the most important advances in palliative care in oncology over the past 15 years has been the recognition that palliative care specialists can improve cancer patients’ outcomes well before their end of life.

Dr. Ricky Shinall

Credit: Vanderbilt University Medical Center

One of the most important advances in palliative care in oncology over the past 15 years has been the recognition that palliative care specialists can improve cancer patients’ outcomes well before their end of life.

Palliative care is specialized care provided to individuals with a serious illness that focuses on decision-making support, pain and symptom management, as well as psychosocial interventions to improve quality of life.

Several past randomized clinical trials have shown palliative care specialists can improve the quality of life and lengthen the survival of patients receiving chemotherapy for metastatic cancer. Other randomized trials have shown palliative care benefits patients undergoing curative treatments, like bone marrow transplantation for hematologic malignancies, or cancers of the blood or blood-forming tissue.

Because of this evidence, in 2016 the American Society of Clinical Oncology recommended specialist palliative care be included along with active treatment for advanced malignancies.

Palliative care specialists and oncology surgeons from Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System have published a study in JAMA Surgery providing evidence that the addition of palliative care services earlier in the disease process, specifically to patients having surgery for cancer, does not demonstrate benefits to the patients. The study also indicates the provision of palliative care at the point of surgery does not increase the patients’ distress or harm them in any way.

“Palliative care specialists are in short supply, so we don’t want to expand the patient population for palliative care specialists without good data that they help that population,” said lead author Myrick “Ricky” Shinall Jr, MD, PhD, associate professor of Surgery and Medicine. “The study was important to test whether this further move upstream in the cancer care continuum would be a good use of a limited resource.

“Prior to the study, I could come up with an explanation of why the intervention would benefit patients since the research had been continually discovering the benefits of specialist palliative care for patients earlier and earlier in the cancer care continuum. I could also come up with the rationale that the issues patients face while undergoing cancer surgery are vastly different than what they face undergoing chemotherapy or stem cell transplant, and they therefore would have much lower levels of unmet palliative care needs and would not show much evidence of benefit from seeing palliative care specialists. It turns out the latter is the case, but we could only know that by doing the trial.”

The study was a randomized clinical trial in which 235 adults undergoing major abdominal operations for cancer were randomly assigned to either an intervention group where they received specialist palliative care or to a control group where they received usual care. The intervention group received a preoperative consultation with a board-certified palliative care physician or nurse practitioner, inpatient visits from these palliative care specialists at least twice weekly during their hospital stay, three follow-up visits or phone calls with the specialists between their hospital discharge and postoperative day 90, and an inpatient palliative care specialist visit if the patient was readmitted to the hospital.

Assessments measured physical and functional quality of life, depression, anxiety, caregiver burden and survival, and there was no evidence that a specialist palliative care intervention significantly improved outcomes. The study did show no adverse effects or additional stress to the patients who received the palliative care intervention.

“One of the concerns people had when the study started was whether incorporating palliative care specialists in perioperative care would distress the patients, and our data really don’t show any evidence of distress or harm caused by the intervention,” Shinall said. “This matches up with our personal experience delivering the palliative care intervention, which we found the patients welcomed. So, one important lesson from this study is that surgeons should not be reluctant to call for palliative care consultations based on a fear this will upset their patients.”

The study team is building on the strengths of this research and designing a new, multicenter randomized control trial (RCT) to test whether a palliative care intervention is beneficial for patients being evaluated for liver transplantation. A second multicenter RCT is also planned to test whether a consultation with geriatricians can improve the outcomes of older surgical oncology patients.

This research was funded by grants K76AG068436, R03AG060085, K12CA090625 and UL1TR002243 from the National Institutes of Health.




Journal

JAMA Surgery

Article Publication Date

10-May-2023

Share12Tweet8Share2ShareShareShare2

Related Posts

Dr. Alex Herrera

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

June 4, 2023
Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

June 3, 2023

ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

June 3, 2023

For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

June 2, 2023

POPULAR NEWS

  • plants

    Plants remove cancer causing toxins from air

    40 shares
    Share 16 Tweet 10
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    36 shares
    Share 14 Tweet 9
  • Deep sea surveys detect over five thousand new species in future mining hotspot

    35 shares
    Share 14 Tweet 9
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Carbon-based stimuli-responsive nanomaterials: classification and application

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In